Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genscript Biotech Corp (OP: GNNSF )

1.410 UNCHANGED
Last Price Updated: 11:16 AM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.410
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.410
Today's Range 1.410 - 1.410
52wk Range 1.050 - 3.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets

Performance

YTD
-31.88%
-31.88%
1 Month
-7.36%
-7.36%
3 Month
-11.88%
-11.88%
6 Month
-7.84%
-7.84%
1 Year
-46.51%
-46.51%

More News

Read More
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
3 DNA Stocks to Buy for the Synthetic Biology Revolution
Via InvestorPlace
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
Via InvestorPlace
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Via Talk Markets
Three Pharma Stocks to Sell Before They Die
Via InvestorPlace
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.